Article Text

Download PDFPDF

2022-RA-1505-ESGO Ovarian cancer retrospective European (O’CaRE) observational study: analysis of first-line (1L) outcomes in patients with ovarian cancer (OC) stratified by number of risk factors for progression
  1. Jonathan Krell1,
  2. Thumulurua K Madhuri2,
  3. Danielle Shaw3,
  4. John McGrane4,
  5. Anjana Anand5,
  6. Andreas Hartkopf6,
  7. Ana Herrero7,
  8. Cheng Yeoh8,
  9. Maria Masvidal9,
  10. Jean-David Fumet10,
  11. Gunther Rogmans11,
  12. Francesco Raspagliesi12,
  13. Celine Gavoille13,
  14. Whitney York14,
  15. Jeanne M Schilder14,
  16. Barbara Mascialino15,
  17. Eleanor McDermott15,
  18. Linda Kalilani16 and
  19. Lars Hanker17
  1. 1Imperial College London, London, UK
  2. 2Royal Surrey NHS Foundation Trust, Guildford, UK
  3. 3The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK
  4. 4Royal Cornwall Hospitals NHS Trust, Cornwall, UK
  5. 5Nottingham University Hospitals NHS Trust, Nottingham, UK
  6. 6Universitätsklinikum Tübingen, Tübingen, Germany
  7. 7Hospital Universitario Miguel Servet, Zaragoza, Spain
  8. 8Queen Alexandra Hospital, Portsmouth, UK
  9. 9Hospital Universitari Sant Joan de Reus, Tarragona, Spain
  10. 10Centre Georges François Leclerc, Dijon, France
  11. 11Helios Klinik, Krefeld, Germany
  12. 12Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
  13. 13Institut de Cancerologie de Lorraine (ICL) Nancy – Unicancer, Vandœuvre-lès-Nancy, France
  14. 14GSK, Philadelphia, PA
  15. 15GSK, Stevenage, UK
  16. 16GSK, Research Triangle, NC
  17. 17Arbeitsgemeinschaft Gynäkologische Onkologie (AGO), University Hospital Schleswig-Holstein, Campus Lübeck, Germany


Introduction/Background The O’CaRE study assessed real-world burden of disease, treatment patterns, and outcomes in patients with OC in 5 European countries (UK, France, Germany, Spain, and Italy). The analysis presented provides real-world data on the cumulative impact of risk factors (RFs) on disease progression and survival following 1L treatment.

Methodology O’CaRE was a multicentre, noninterventional retrospective medical chart review study of patients aged ≥18 years diagnosed with epithelial ovarian, fallopian tube, or primary peritoneal cancer from 1 January 2014 to 31 December 2015. Patients were classified into moderate- or high-risk categories based on number of RFs for progression (Table). High-risk patients were further grouped by total number of RFs. Patients were followed from index date (date of diagnosis) until last activity or study end (maximum follow of 4 years). Kaplan-Meier methodology was used to estimate progression-free survival (PFS) and overall survival (OS).

Results The analysis included 412 patients: 7 (1.7%) had moderate risk of progression, whereas 405 (98%) had high risk of progression (table 1). For those with high risk, 84 (20.4%), 133 (32.3%), 139 (33.7%), and 49 (11.9%) had 1, 2, 3, and 4 RFs, respectively. Median PFS was 31.3 months for patients with 0 RFs and 12.6, 7.9, 5.9, and 3.5 months for patients with 1, 2, 3, or 4 RFs, respectively. Median OS was 41.9 months for patients with 0 RFs and not reached, 25.0, 18.0, and 7.4 months for patients with 1, 2, 3, or 4 RFs, respectively.

Abstract 2022-RA-1505-ESGO Table 1

Outcomes by risk factors

Conclusion This real-world analysis of patients with OC from 5 European countries demonstrated that higher numbers of RFs were associated with shorter median PFS and OS. This analysis provides real-world data relating to 1L treatment outcomes for patients with OC; if validated in clinical trials, the number of RFs could be a stratification factor for future 1L OC trials.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.